A citation-based method for searching scientific literature

Qinghua Jiang, Mingxue Li, Hua Li, Lixia Chen. Biomed Pharmacother 2022
Times Cited: 1







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Optimization of a novel kinase inhibitor scaffold for the dual inhibition of JAK2 and FAK kinases.
Craig A Zificsak, Diane E Gingrich, Henry J Breslin, Derek D Dunn, Karen L Milkiewicz, Jay P Theroff, Tho V Thieu, Ted L Underiner, Linda R Weinberg, Lisa D Aimone,[...]. Bioorg Med Chem Lett 2012
14
100

Design, synthesis, and biological evaluation of novel FAK scaffold inhibitors targeting the FAK-VEGFR3 protein-protein interaction.
Priyanka N Gogate, Manivannan Ethirajan, Elena V Kurenova, Andrew T Magis, Ravindra K Pandey, William G Cance. Eur J Med Chem 2014
21
100

Mitoxantrone targets the ATP-binding site of FAK, binds the FAK kinase domain and decreases FAK, Pyk-2, c-Src, and IGF-1R in vitro kinase activities.
Vita M Golubovskaya, Baotran Ho, Min Zheng, Andrew Magis, David Ostrov, William G Cance. Anticancer Agents Med Chem 2013
12
100


FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapy.
Carlos J Diaz Osterman, Duygu Ozmadenci, Elizabeth G Kleinschmidt, Kristin N Taylor, Allison M Barrie, Shulin Jiang, Lisa M Bean, Florian J Sulzmaier, Christine Jean, Isabelle Tancioni,[...]. Elife 2019
46
100

mTOR: from growth signal integration to cancer, diabetes and ageing.
Roberto Zoncu, Alejo Efeyan, David M Sabatini. Nat Rev Mol Cell Biol 2011
100

Selectivity switch between FAK and Pyk2: Macrocyclization of FAK inhibitors improves Pyk2 potency.
Julie Farand, Nicholas Mai, Jayaraman Chandrasekhar, Zachary E Newby, Josh Van Veldhuizen, Jennifer Loyer-Drew, Chandrasekar Venkataramani, Juan Guerrero, Amy Kwok, Ning Li,[...]. Bioorg Med Chem Lett 2016
13
100

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.
Susumu Kobayashi, Titus J Boggon, Tajhal Dayaram, Pasi A Jänne, Olivier Kocher, Matthew Meyerson, Bruce E Johnson, Michael J Eck, Daniel G Tenen, Balázs Halmos. N Engl J Med 2005
100

Emerging roles of focal adhesion kinase in cancer.
Yu-Ling Tai, Lih-Chyang Chen, Tang-Long Shen. Biomed Res Int 2015
140
100

STAT3 as a central regulator of tumor metastases.
Eswaran Devarajan, Suyun Huang. Curr Mol Med 2009
134
100


Structure-kinetic relationship reveals the mechanism of selectivity of FAK inhibitors over PYK2.
Benedict-Tilman Berger, Marta Amaral, Daria B Kokh, Ariane Nunes-Alves, Djordje Musil, Timo Heinrich, Martin Schröder, Rebecca Neil, Jing Wang, Iva Navratilova,[...]. Cell Chem Biol 2021
11
100

Histone deacetylase (HDAC) 1 and 2 expression and chemotherapy in gastric cancer.
Kathrin Mutze, Rupert Langer, Karen Becker, Katja Ott, Alexander Novotny, Birgit Luber, Alexander Hapfelmeier, Martin Göttlicher, Heinz Höfler, Gisela Keller. Ann Surg Oncol 2010
52
100

Multikinase Inhibitor CT-707 Targets Liver Cancer by Interrupting the Hypoxia-Activated IGF-1R-YAP Axis.
Hong Zhu, Dan-Dan Wang, Tao Yuan, Fang-Jie Yan, Chen-Ming Zeng, Xiao-Yang Dai, Zi-Bo Chen, Ying Chen, Tianyi Zhou, Guang-Han Fan,[...]. Cancer Res 2018
22
100


Organization and post-transcriptional processing of focal adhesion kinase gene.
Jean-Marc Corsi, Evelyne Rouer, Jean-Antoine Girault, Hervé Enslen. BMC Genomics 2006
57
100

A first-in-class anticancer dual HDAC2/FAK inhibitors bearing hydroxamates/benzamides capped by pyridinyl-1,2,4-triazoles.
Muhamad Mustafa, Amer Ali Abd El-Hafeez, Dalia Abdelhamid, Gajanan D Katkar, Yaser A Mostafa, Pradipta Ghosh, Alaa M Hayallah, Gamal El-Din A Abuo-Rahma. Eur J Med Chem 2021
5
100

FAK-targeted and combination therapies for the treatment of cancer: an overview of phase I and II clinical trials.
Atish Mohanty, Rebecca R Pharaon, Arin Nam, Sabrina Salgia, Prakash Kulkarni, Erminia Massarelli. Expert Opin Investig Drugs 2020
36
100

Targeting FAK scaffold functions inhibits human renal cell carcinoma growth.
Claire Béraud, Valérian Dormoy, Sabrina Danilin, Véronique Lindner, Audrey Béthry, Mazène Hochane, Catherine Coquard, Mariette Barthelmebs, Didier Jacqmin, Hervé Lang,[...]. Int J Cancer 2015
19
100

The histone deacetylases HDAC1 and HDAC2 are required for the growth and survival of renal carcinoma cells.
Nicole Kiweler, Boris Brill, Matthias Wirth, Ines Breuksch, Teresa Laguna, Cornelia Dietrich, Susanne Strand, Günter Schneider, Bernd Groner, Falk Butter,[...]. Arch Toxicol 2018
37
100

HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.
Rekha Sangwan, Remya Rajan, Pintu Kumar Mandal. Eur J Med Chem 2018
46
100


PND-1186 FAK inhibitor selectively promotes tumor cell apoptosis in three-dimensional environments.
Isabelle Tanjoni, Colin Walsh, Sean Uryu, Alok Tomar, Ju-Ock Nam, Ainhoa Mielgo, Ssang-Taek Lim, Congxin Liang, Marcel Koenig, Connie Sun,[...]. Cancer Biol Ther 2010
117
100

Vascular endothelial growth factor receptor 3 is involved in tumor angiogenesis and growth.
Pirjo Laakkonen, Marika Waltari, Tanja Holopainen, Takashi Takahashi, Bronislaw Pytowski, Philipp Steiner, Daniel Hicklin, Kris Persaud, James R Tonra, Larry Witte,[...]. Cancer Res 2007
175
100


Nuclear FAK controls chemokine transcription, Tregs, and evasion of anti-tumor immunity.
Alan Serrels, Tom Lund, Bryan Serrels, Adam Byron, Rhoanne C McPherson, Alexander von Kriegsheim, Laura Gómez-Cuadrado, Marta Canel, Morwenna Muir, Jennifer E Ring,[...]. Cell 2015
216
100

Vascular endothelial growth factor-C and its receptor VEGFR-3 in non-small-cell lung cancer: concurrent expression in cancer cells from primary tumour and metastatic lymph node.
Pierre Saintigny, Marianne Kambouchner, Madani Ly, Noëlia Gomes, Odile Sainte-Catherine, Roger Vassy, Sébastien Czernichow, Philippe Letoumelin, Jean-Luc Breau, Jean-François Bernaudin,[...]. Lung Cancer 2007
57
100

4
100

Selective inhibition of BET bromodomains.
Panagis Filippakopoulos, Jun Qi, Sarah Picaud, Yao Shen, William B Smith, Oleg Fedorov, Elizabeth M Morse, Tracey Keates, Tyler T Hickman, Ildiko Felletar,[...]. Nature 2010
100


Variations of proline-rich kinase Pyk2 expression correlate with prostate cancer progression.
R Stanzione, A Picascia, P Chieffi, C Imbimbo, A Palmieri, V Mirone, S Staibano, R Franco, G De Rosa, J Schlessinger,[...]. Lab Invest 2001
42
100

Molecular Pathways: Endothelial Cell FAK-A Target for Cancer Treatment.
Marina Roy-Luzarraga, Kairbaan Hodivala-Dilke. Clin Cancer Res 2016
55
100

Perforated duodenal ulcer associated with anterior abdominal abscess: A case report.
Sun Zhonghua, Awaji Al-Naami, Ali Khan Liaqat. Australas Med J 2012
4
100

Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors.
Jeffrey R Infante, D Ross Camidge, Linda R Mileshkin, Eric X Chen, Rodney J Hicks, Danny Rischin, Howard Fingert, Kristen J Pierce, Huiping Xu, W Gregory Roberts,[...]. J Clin Oncol 2012
166
100

FAK and S6K1 Inhibitor, Neferine, Dually Induces Autophagy and Apoptosis in Human Neuroblastoma Cells.
Dinh-Chuong Pham, Yu-Chuan Chang, Shian-Ren Lin, Yuh-Ming Fuh, May-Jywan Tsai, Ching-Feng Weng. Molecules 2018
20
100

Carcinoma-associated eIF3i overexpression facilitates mTOR-dependent growth transformation.
Martin Ahlemann, Reinhard Zeidler, Stephan Lang, Brigitte Mack, Markus Münz, Olivier Gires. Mol Carcinog 2006
42
100

Targeting EGFRL858R/T790M and EGFRL858R/T790M/C797S resistance mutations in NSCLC: Current developments in medicinal chemistry.
Xiaoyun Lu, Lei Yu, Zhang Zhang, Xiaomei Ren, Jeff B Smaill, Ke Ding. Med Res Rev 2018
58
100

Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors.
Amr K A Bass, Mona S El-Zoghbi, El-Shimaa M Nageeb, Mamdouh F A Mohamed, Mohamed Badr, Gamal El-Din A Abuo-Rahma. Eur J Med Chem 2021
13
100

Aberrant regulation of HDAC2 mediates proliferation of hepatocellular carcinoma cells by deregulating expression of G1/S cell cycle proteins.
Ji Heon Noh, Kwang Hwa Jung, Jeong Kyu Kim, Jung Woo Eun, Hyun Jin Bae, Hong Jian Xie, Young Gyoon Chang, Min Gyu Kim, Won Sang Park, Jung Young Lee,[...]. PLoS One 2011
73
100

Discovery of Clinical Candidate CEP-37440, a Selective Inhibitor of Focal Adhesion Kinase (FAK) and Anaplastic Lymphoma Kinase (ALK).
Gregory R Ott, Mangeng Cheng, Keith S Learn, Jason Wagner, Diane E Gingrich, Joseph G Lisko, Matthew Curry, Eugen F Mesaros, Arup K Ghose, Matthew R Quail,[...]. J Med Chem 2016
43
100

FAK in cancer: mechanistic findings and clinical applications.
Florian J Sulzmaier, Christine Jean, David D Schlaepfer. Nat Rev Cancer 2014
748
100

HDAC1 and HDAC2 independently predict mortality in hepatocellular carcinoma by a competing risk regression model in a Southeast Asian population.
Ser Yeng Ler, Carol Ho Wing Leung, Lay Wai Khin, Guo-Dong Lu, Manuel Salto-Tellez, Mikael Hartman, Philip Tsau Choong Iau, Celestial T Yap, Shing Chuan Hooi. Oncol Rep 2015
52
100

Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1.
B H Huang, M Laban, C H-W Leung, L Lee, C K Lee, M Salto-Tellez, G C Raju, S C Hooi. Cell Death Differ 2005
259
100

ALK inhibitors in non-small cell lung cancer: the latest evidence and developments.
Ivana Sullivan, David Planchard. Ther Adv Med Oncol 2016
78
100


Understanding the roles of FAK in cancer: inhibitors, genetic models, and new insights.
Hyunho Yoon, Joshua P Dehart, James M Murphy, Ssang-Taek Steve Lim. J Histochem Cytochem 2015
111
100


Fragment-based discovery of new highly substituted 1H-pyrrolo[2,3-b]- and 3H-imidazolo[4,5-b]-pyridines as focal adhesion kinase inhibitors.
Timo Heinrich, Jeyaprakashnarayanan Seenisamy, Lourdusamy Emmanuvel, Santosh S Kulkarni, Jörg Bomke, Felix Rohdich, Hartmut Greiner, Christina Esdar, Mireille Krier, Ulrich Grädler,[...]. J Med Chem 2013
42
100

RAFTK/Pyk2-mediated cellular signalling.
H Avraham, S Y Park, K Schinkmann, S Avraham. Cell Signal 2000
390
100

Vascular endothelial growth factor receptor-3 promotes breast cancer cell proliferation, motility and survival in vitro and tumor formation in vivo.
Elena V Kurenova, Darrell L Hunt, Dihua He, Ann D Fu, Nicole A Massoll, Vita M Golubovskaya, Christopher A Garces, William G Cance. Cell Cycle 2009
34
100


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.